298 related articles for article (PubMed ID: 33531609)
21. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with recurrent oral squamous cell carcinoma treated with nivolumab.
Tachinami H; Tomihara K; Yamada SI; Ikeda A; Imaue S; Hirai H; Nakai H; Sonoda T; Kurohara K; Yoshioka Y; Hasegawa T; Naruse T; Niiyama T; Shimane T; Ueda M; Yanamoto S; Akashi M; Umeda M; Kurita H; Miyazaki A; Arai N; Hayashi R; Noguchi M
Br J Oral Maxillofac Surg; 2023 May; 61(4):320-326. PubMed ID: 37061418
[TBL] [Abstract][Full Text] [Related]
22. Association between the C-reactive protein/albumin ratio and prognosis in patients with oral squamous cell carcinoma.
Yamagata K; Fukuzawa S; Ishibashi-Kanno N; Uchida F; Bukawa H
Sci Rep; 2021 Mar; 11(1):5446. PubMed ID: 33686103
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Yamashita G; Okamoto I; Ito T; Tokashiki K; Okada T; Tsukahara K
Anticancer Res; 2023 Aug; 43(8):3679-3683. PubMed ID: 37500154
[TBL] [Abstract][Full Text] [Related]
24. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
[TBL] [Abstract][Full Text] [Related]
26. Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab.
Hirai Y; Kurihara K; Sano D; Inamo M; Takahashi H; Ichikawa Y; Oridate N
In Vivo; 2023; 37(6):2687-2695. PubMed ID: 37905649
[TBL] [Abstract][Full Text] [Related]
27. Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma.
Ramakrishnan K; Liu Z; Baxi S; Chandwani S; Joo S; Chirovsky D
Future Oncol; 2021 Aug; 17(23):3037-3050. PubMed ID: 34044594
[TBL] [Abstract][Full Text] [Related]
28. Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study.
Kondo T; Okamoto I; Sato H; Koyama N; Fushimi C; Okada T; Masubuchi T; Miura K; Matsuki T; Yamashita T; Omura G; Takahashi H; Tsukahara K
Asia Pac J Clin Oncol; 2020 Dec; 16(6):340-347. PubMed ID: 32573033
[TBL] [Abstract][Full Text] [Related]
29. Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma.
Inoue H; Yokota T; Hamauchi S; Onozawa Y; Kawakami T; Shirasu H; Notsu A; Yasui H; Onitsuka T
Auris Nasus Larynx; 2020 Aug; 47(4):650-657. PubMed ID: 32035695
[TBL] [Abstract][Full Text] [Related]
30. Neutrophil-to-lymphocyte ratio: Prognostic indicator for head and neck squamous cell carcinoma.
Rosculet N; Zhou XC; Ha P; Tang M; Levine MA; Neuner G; Califano J
Head Neck; 2017 Apr; 39(4):662-667. PubMed ID: 28075517
[TBL] [Abstract][Full Text] [Related]
31. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
32. High pretreatment neutrophil-to-lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: Systematic review and meta-analysis.
Yang L; Huang Y; Zhou L; Dai Y; Hu G
Head Neck; 2019 May; 41(5):1525-1535. PubMed ID: 30597654
[TBL] [Abstract][Full Text] [Related]
33. [Neutrophil-to-Lymphocyte Ratio(NLR)as a Predictive Indicator of the Response to Nivolumab in Patients with Oral Squamous Cell Carcinoma].
Tachinami H; Tomihara K; Ikeda A; Sekido K; Sakurai K; Imaue S; Fujiwara K; Hayashi R; Noguchi M
Gan To Kagaku Ryoho; 2021 Dec; 48(12):1485-1490. PubMed ID: 34911916
[TBL] [Abstract][Full Text] [Related]
34. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
[TBL] [Abstract][Full Text] [Related]
35. Postoperative C-reactive protein/albumin ratio is a biomarker of risk of recurrence and need for adjuvant chemotherapy for stage III colorectal cancer.
Matsuoka H; Ando K; Hu Q; Zaitsu Y; Tsuda Y; Hisamatsu Y; Nakashima Y; Kimura Y; Oki E; Mori M
Int J Clin Oncol; 2020 Jul; 25(7):1318-1326. PubMed ID: 32279124
[TBL] [Abstract][Full Text] [Related]
36. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
Bojaxhiu B; Templeton AJ; Elicin O; Shelan M; Zaugg K; Walser M; Giger R; Aebersold DM; Dal Pra A
Radiat Oncol; 2018 Nov; 13(1):216. PubMed ID: 30400969
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck.
Reverdy T; Varnier R; de Talhouët S; Duplomb S; Bruyas A
Oral Oncol; 2023 Oct; 145():106533. PubMed ID: 37562096
[TBL] [Abstract][Full Text] [Related]
38. Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Guiard E; Clatot F; Even C; Perréard M; Abdeddaim C; Johnson A; Vauléon E; Rambeau A
Eur J Cancer; 2021 Dec; 159():125-132. PubMed ID: 34743067
[TBL] [Abstract][Full Text] [Related]
39. Usefulness of Hematological Inflammatory Markers in Predicting Severe Side-effects from Induction Chemotherapy in Head and Neck Cancer Patients.
Mikoshiba T; Ozawa H; Saito S; Ikari Y; Nakahara N; Ito F; Watanabe Y; Sekimizu M; Imanishi Y; Ogawa K
Anticancer Res; 2019 Jun; 39(6):3059-3065. PubMed ID: 31177149
[TBL] [Abstract][Full Text] [Related]
40. Site of distant metastasis affects the prognosis with recurrent/metastatic head and neck squamous cell carcinoma patients treated with Nivolumab.
Hoshi Y; Shirakura S; Yamada M; Sugiyama T; Koide N; Tamii S; Kamata K; Yokomura M; Osaki S; Ohno T; Yagihara K; Hara H; Beppu T
Int J Clin Oncol; 2023 Sep; 28(9):1139-1146. PubMed ID: 37421478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]